Your session is about to expire
← Back to Search
Triple Drug Combo for Advanced Cancer
Study Summary
This trial is testing the side effects and best dose of copanlisib and olaparib when given together with durvalumab, and how well they work in treating patients with metastatic or unresectable solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has Durvalumab gained authorization from the Food and Drug Administration?
"Durvalumab's safety has been documented, but only in a limited capacity. Consequently, the risk level of this drug is assessed as 1 on our team's scale."
What is the general purpose of Durvalumab treatment?
"Durvalumab is commonly used as a supplementary treatment for chemotherapy and has been successful in treating primary peritoneal cancer, therapeutic procedures, and pharmacotherapies."
How many participants have been included in this experiment?
"Affirmative, the information on clinicaltrials.gov provides evidence that this trial is still seeking applicants. It was initially posted in August 2019 and amended most recently in November 2022, with a need for 108 volunteers from 6 sites."
Could you please provide a synopsis of the previous investigations into Durvalumab's efficacy?
"Durvalumab was first studied in 2005 at Research Site and has since seen 313 trials to completion. Presently, there are 513 active clinical studies involving durvalumab across the globe; of which many are located in Austin, Texas."
Is this experiment the first of its kind?
"A search of clinicaltrials.gov reveals that 513 live studies concerning Durvalumab are distributed across 65 nations and 2012 cities. The earliest trial associated with this medication was held in 2005, sponsored by AstraZeneca, which involved 98 patients and ultimately achieved Phase 1 drug approval status. Since then, 313 follow-up trials have been administered."
Are enrollees still being accepted into this research experiment?
"According to clinicaltrials.gov, this medical trial is actively recruiting patients. The initial posting of the study occurred on August 12th 2019 and was last updated November 8th 2022."
Share this study with friends
Copy Link
Messenger